Obagi Medical Enrolls 17 ProMD Clinics in ALOHA MagIQ Evaluation
Waldencast’s Obagi Medical has enrolled ProMD Health’s 17-location network in its ALOHA Program to evaluate saypha MagIQ alongside integrated skincare protocols. Standardized data across multiple states will underpin real-world evidence for MagIQ’s clinical efficacy and patient experience.
1. Program Launch
On March 19, Waldencast’s Obagi Medical announced a collaboration with ProMD Health to incorporate its 17-practice network into the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. ProMD was selected for its multi-state footprint and clinical rigor, marking the first time MagIQ will undergo independent, structured evaluation across an external provider network.
2. Evaluation Framework
The ALOHA Program unites clinical education from Obagi’s national trainers with ProMD injector expertise, deploying integrated skincare protocols alongside MagIQ injections. Participating providers will collect standardized efficacy, safety and patient satisfaction data across all sites, ensuring consistent measurement of clinical endpoints and post-care outcomes.
3. MagIQ Technology
Obagi® saypha® MagIQ™, developed with proprietary MACRO Core Technology, features a three-dimensional hyaluronic acid matrix designed for uniform gel distribution, high usable HA content and predictable injection performance. The program will assess its comparative injection force, swelling profile and patient-reported outcomes to validate category-leading performance in real-world settings.
4. Strategic Implications
This partnership reinforces Obagi’s evidence-based launch model, leveraging multi-location practices to accelerate market adoption and build robust real-world evidence for MagIQ. Positive clinical and patient experience results could bolster Waldencast’s professional channel growth and support broader integration of MagIQ into advanced aesthetic treatment protocols.